Aclaris Therapeutics, Inc. (ACRS) скачать в хорошем качестве

Aclaris Therapeutics, Inc. (ACRS)

Aclaris Therapeutics, Inc. (ACRS) Analysis Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for immune-mediated inflammatory diseases. Financial Overview Revenue: In 2024, Aclaris reported revenue of approximately $18.72 million, which was about 40% lower than the previous year. Net Loss: The net loss for 2024 was $132.07 million, representing a 49.3% increase compared to the prior year. Earnings Per Share (EPS): The EPS stood at -$1.45. Market Capitalization: Around $159 million. Product Development and Research Aclaris is developing several drug candidates, including ATI-1777, a JAK1/3 inhibitor currently in Phase 2b clinical trials. Another candidate, ATI-2138, an ITK/JAK3 inhibitor, is in Phase 2a. These drugs aim to treat conditions such as atopic dermatitis and psoriasis. Analyst Opinions Several analysts rate Aclaris stock as a "Strong Buy." The 12-month price target ranges from $7.00 to $16.00, with an average target of $9.71, suggesting a potential upside of around 560% from the current price. Summary While Aclaris Therapeutics faces financial challenges, its promising drug pipeline offers significant future potential. Investors should carefully consider the company’s financial position and market risks before making investment decisions.